Imaging Biometrics, LLC working to improve MRI results in Europe
Imaging Biometrics, LLC has signed an agreement with the European Organisation for Research and Treatment of Cancer (EORTC) to evaluate MRI datasets using its proprietary dynamic susceptibility contrast (DSC) MRI perfusion software, IB Neuro.
“We are delighted that the EORTC has contracted with us to assist them in these important clinical initiatives”, said Michael Schmainda, IB’s President and CEO. “IB Neuro is renowned for its ability to accurately discriminate between tissue types and we look forward to working with the EORTC and advancing healthcare.”
IB Neuro uses DSC algorithms to provide information about blood volume and blood flow in the brain. These critical perfusion parameters are valuable for detecting new tumor growth or tumor recurrence, and should assist in tailoring personalized treatment plans for patients. MR perfusion imaging may also play an important role in the development of improved treatment therapies, which is another objective of these studies.
Cleared by the U.S. Food and Drug Administration (FDA), IB Neuro incorporates proprietary algorithms to correct for contrast agent leakage to more consistently distinguish between normal and abnormal tissue. This rich information should enable better decisions in tailoring individual treatment plans for patients with brain tumors and other brain disorders.
Imaging Biometrics primarily develops client-centric, ready to use software for the healthcare industry.